Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis

1Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Worcester, MA;

2Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; and

3Transilvania University of Brasov, Romania, Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Brasov, Romania.

*Address for correspondence: Professor Lorena Dima, MD, PhD, Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Transilvania University of Brasov, Romania, 56 Nicolae Bălcescu Str, Brasov 500019, Romania. E-mail: [email protected]

The authors have no conflicts of interest to declare.

This article is part of a series evaluating drugs recently approved by the US Food and Drug Administration. The series is coordinated by Timothy Nguyen, PharmD, and Kristine Willett, PharmD.

留言 (0)

沒有登入
gif